CME Group (CME) came out with quarterly earnings of $2.52 per share, beating the Zacks Consensus Estimate of $2.44 per share. This compares to earnings of $2.37 per share a year ago.
CME Group (CME -0.03%), a leading derivatives marketplace known for options and futures trading, reported fourth-quarter 2024 earnings results on Wednesday, Feb. 12, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) of $2.52 beat the estimate of $2.45.
CME's fourth-quarter results are likely to reflect a diverse product portfolio, increased volatility and a strong market position.
Evaluate the expected performance of CME (CME) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CME (CME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I believe we are entering the perfect stock-picking market as valuations shift. With economic growth widening, opportunities beyond big tech are emerging. One of my highest-conviction picks is a unique landowner. Its high-margin business model benefits from oil, water, and data center deals. The other pick is a high-margin financial giant. With strong cash flow, minimal capital needs, and dividend potential, I see massive upside ahead.
Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.
Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.
CME (CME) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Rising interest rates and a significant portion of U.S. debt maturing soon pose a major risk to the economy and stock market. Elevated bond yields provide an attractive alternative to equities, making the market vulnerable to further increases in longer-term bond rates. Inflation remains a critical risk, potentially leading to higher fed funds rates and bond yields, which could negatively impact stock prices.
A strong global presence, a compelling product portfolio, focus on over-the-counter clearing services and a solid capital position poise CME well for growth.
CME Group gets upgraded to buy, from my prior hold rating over a year ago, with renewed confidence in its future top and bottom-line growth potential. The firm could be driven by increased trading volume, but also growing demand for data analytics solutions. The dividend case is strong: a +4% yield, proven dividend growth, and a safe payout ratio.